Evaluation of 64Cu-Labeled New Anti-EGFR Antibody NCAB001 with Intraperitoneal Injection for Early PET Diagnosis of Pancreatic Cancer in Orthotopic Tumor-Xenografted Mice and Nonhuman Primates.
Hiroki MatsumotoTadashi WatabeChika IgarashiTomoko TachibanaFukiko HiharaAtsuo WakiMing-Rong ZhangHideaki TashimaTaiga YamayaKazuhiro OoeEku ShimosegawaJun HatazawaSei YoshidaKenichiro NaitoHiroaki KuriharaMakoto UenoKimiteru ItoTatsuya HigashiYukie YoshiiPublished in: Pharmaceuticals (Basel, Switzerland) (2021)
Our data support the initiation of clinical trials of 64Cu-NCAB001 ipPET to transfer this promising tool for the early diagnosis of pancreatic cancers.
Keyphrases
- clinical trial
- pet imaging
- small cell lung cancer
- aqueous solution
- epidermal growth factor receptor
- tyrosine kinase
- computed tomography
- electronic health record
- high fat diet induced
- pet ct
- metal organic framework
- positron emission tomography
- big data
- ultrasound guided
- phase ii
- machine learning
- adipose tissue
- phase iii